Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update (2020)

Peer-Reviewed Study · Tier 1 — Primary Document · Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. (American Society of Clinical Oncology) · October 1, 2020

Loprinzi CL et al., 2020-10-01: The current ASCO guideline update on CIPN. It recommends no agent for prevention, discourages acetyl-L-carnitine, and endorses only duloxetine, with limited benefit, for established painful CIPN.

Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.

Abstract (Recommendations); full text section 'Prevention'

Loprinzi CL et al., 2020-10-01: The current ASCO guideline update on CIPN. It recommends no agent for prevention, discourages acetyl-L-carnitine, and endorses only duloxetine, with limited benefit, for established painful CIPN. Funder/COI: ASCO guideline panel, with disclosures published with the article; no industry sponsor of the guideline itself stated in the text read. Comparator: the trials reviewed (placebo-controlled). Verbatim on the other agents the brief asks about, from the same full text (Appendix Table A1 and 'Literature Review Update'): alpha-lipoic acid – 'The study results suggest that ALA is not tolerated well and does not prevent neuropathy.'; vitamin B – guideline table lists 'Vitamin B' under agents with 'evidence based, no benefits', and the text records a 71-patient placebo-controlled trial in which 'there was no suggestion that the primary end point was improved in the vitamin B arm'; acupuncture – 'Outside the context of a clinical trial, no recommendations can be made on the use of the following interventions for the prevention of CIPN: Acupuncture…'. All four quotes are from the free full text at the source_url. Study type: review.